(BWAY) BrainsWay Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BWAY) BrainsWay Ltd. Complete Analysis Pack
Unlock Strategic Clarity
This BrainsWay Ltd. 4P's Marketing Mix Analysis shows how the company’s Product, Price, Place, and Promotion choices support its market positioning and sales; the page includes a real preview/sample of the analysis so you can judge style and substance. Purchase the full version to get the complete, ready-to-use company-specific report.
Product
Deep TMS platform
BrainsWay’s Deep TMS platform is its core offering, a non-invasive neurostimulation system used in office-based mental health and neurological care. The company has reported regulatory reach across major indications, including depression, OCD, and smoking cessation, which supports repeat clinic use and a broader installed-base strategy. This product sits at the center of BrainsWay’s 4P mix because it drives both clinical adoption and recurring treatment-volume demand.
Non-invasive therapy
BrainsWay Ltd.'s non-invasive therapy is delivered externally with magnetic stimulation, so it avoids surgery and anesthesia and fits outpatient care. The sessions are clinic-based and typically take about 20 minutes, which helps patients return to normal activity the same day. This ease of use supports wider adoption in psychiatry centers treating depression, OCD, and smoking cessation.
Broad indication portfolio
BrainsWay’s broad indication portfolio spans 13 conditions, from major depressive disorder and OCD to PTSD, schizophrenia, Alzheimer’s disease, and Parkinson’s disease. That reach lets the Company sell across psychiatry and neurology, not just one niche. A wider clinical addressable market also gives the brand more shots at adoption in high-need patient groups.
Professional medical device
BrainsWay Ltd. sells a professional medical device to medical professionals, hospitals, and medical centers, so the product is built for clinician-led treatment, not consumer self-use. That keeps the value prop tied to measured outcomes, trained workflows, and reimbursement-ready care. In 2025, this B2B model supports repeat placements and service use, which matters more than one-off device sales.
- Clinician-administered, not self-use.
- Targets hospitals and medical centers.
- Sales depend on clinical outcomes.
- Workflow fit drives adoption.
H-coil based system
BrainsWay Ltd.’s Deep TMS uses its proprietary H-coil, and that coil is the core of how the treatment reaches deeper brain regions than standard figure-8 TMS systems. The design is a key product differentiator and supports the platform’s use across multiple psychiatric and neurologic indications.
- Proprietary H-coil drives Deep TMS delivery
- Targets deeper brain areas than standard TMS
- Installed base exceeded 1,000 systems worldwide
- Supports BrainsWay Ltd.’s clinical differentiation
BrainsWay’s Deep TMS Expands Reach Across 13 Indications
BrainsWay Ltd.’s Product is its Deep TMS system, a clinician-led, non-invasive therapy for depression, OCD, smoking cessation, and more. The proprietary H-coil is the key edge, reaching deeper brain areas than standard TMS. With 13 indications and over 1,000 systems installed worldwide, the Product supports broad hospital and clinic adoption.
| Metric | Data |
|---|---|
| Indications | 13 |
| Installed systems | 1,000+ |
| Delivery | Non-invasive, outpatient |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of BrainsWay Ltd. covering Product, Price, Place, and Promotion with real-world strategic context.
Editable Excel File
Condenses BrainsWay’s 4Ps into a quick, easy-to-scan snapshot that relieves time pressure and speeds up strategic discussion.
Reference Sources
Provides a concise, traceable list of primary industry reports, clinical trial data, and regulatory sources to speed due diligence and verify BrainsWay Ltd. assumptions.
Place
Direct institutional sales
BrainsWay Ltd. sells through direct B2B institutional sales, so the buyer is a clinic or hospital, not a retail patient. In 2025, its H1 revenue was $29.6 million, showing how the channel depends on large, recurring account wins. That makes sales highly specialized, with long cycles, demos, and close account management.
United States market
The United States is BrainsWay Ltd.’s core commercial market, with 340 million+ people and the world’s largest medical device spend. That scale matters for clinic penetration, since U.S. adoption often sets the pace for TMS growth and payer access.
Reimbursement is a key driver: Medicare covers TMS for treatment-resistant depression, and commercial coverage widens clinic adoption. In 2025, BrainsWay kept using the U.S. to deepen installed base and convert access into recurring treatment volume.
For a device company, the U.S. is where sales, reimbursement, and physician trust meet. BrainsWay’s U.S. footprint is therefore central to revenue mix and long-term market share.
Europe market
BrainsWay Ltd. has a Europe presence through its distribution network, so its Deep TMS platform is not tied to one market. That wider reach supports adoption across more clinics and payers, and it helps the brand build international scale beyond the U.S. In 2025, this cross-border footprint remained important for market expansion.
Israel headquarters
BrainsWay Ltd. is headquartered in Jerusalem, Israel, which anchors its corporate and operational base. The city location reflects the company’s Israeli origin and supports its global management structure. For Place in the 4P mix, this gives BrainsWay a clear home market identity and a centralized decision hub.
- Headquarters: Jerusalem, Israel
- Corporate and operational base
- Supports global management control
Global medical channel
BrainsWay’s global medical channel reaches markets outside the United States, Europe, and Israel through hospitals, psychiatric centers, and specialty clinics. That is a high-trust, regulated route, so buying decisions depend on clinical evidence, physician adoption, and local reimbursement rules.
- Hospital-led, clinician-driven sales
- Built for regulated markets
- Best fit for specialty care sites
BrainsWay’s U.S.-Led B2B Distribution Drives $29.6M H1 2025 Revenue
BrainsWay Ltd.’s Place is a direct, regulated B2B route: it sells Deep TMS to clinics, hospitals, and specialty centers, mainly in the United States, then extends through Europe and other markets. In H1 2025, revenue was $29.6 million, showing the channel depends on account wins, reimbursement, and clinical adoption. Headquarters in Jerusalem supports global control.
| Place factor | Key data |
|---|---|
| Core market | United States |
| H1 2025 revenue | $29.6 million |
| HQ | Jerusalem, Israel |
Preview the Actual Deliverable
BrainsWay Ltd. Reference Sources
The preview shown here is the actual BrainsWay Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Clinical evidence
BrainsWay promotes its platform through clinical evidence, and that matters in medical devices where physicians want proof before they buy. In 2025, this evidence-first pitch stayed central to adoption because peer-reviewed results and cleared indications help reduce clinical risk and support reimbursement talks. The point is simple: stronger data drives trust, and trust drives use.
Medical conference presence
BrainsWay Ltd. can use psychiatry and neurology conferences to reach specialist buyers where they already look for device education and clinical data. This channel matters because conference floors and symposia let the company show Deep TMS use cases, train clinicians, and build trust with prescribers. In healthcare devices, face-to-face education still drives awareness and adoption, especially among high-value referral networks.
Physician education
Physician education is central for BrainsWay Ltd., because its main buyers are psychiatrists and other medical specialists who must trust the device, the protocol, and the workflow. Training helps doctors choose the right patients, use the system correctly, and fit Deep TMS into busy clinic schedules. That matters for adoption in specialty practices, where reimbursement, throughput, and clinical fit drive use.
Key opinion leaders
BrainsWay Ltd. can use key opinion leaders, such as psychiatrists and clinic users, to turn clinical evidence for Deep TMS into day-to-day adoption. In 2025, the company kept expanding across multiple FDA-cleared uses, so expert advocacy helps reduce buyer risk and speed clinician trust in a high-touch device market.
- Clinical advocates boost credibility
- Expert users shorten adoption cycles
- KOLs bridge data and practice
Regulatory and reimbursement messaging
BrainsWay Ltd.’s promotion leans on cleared indications and payer access, because clinic buyers want proof that Deep TMS fits a reimbursable path. That matters in a market where reimbursement status can decide whether a new device gets used at all.
The message lowers adoption friction by showing regulatory clearance, coverage support, and a short route to patient access. BrainsWay has more than 1,300 installed systems worldwide, so this messaging helps convert a large installed base into repeat clinic use.
For buyers, the pitch is simple: less reimbursement uncertainty, faster onboarding, and lower sales risk. That is especially important in neuropsychiatry, where treatment economics often matter as much as clinical fit.
- Highlights cleared indications
- Shows reimbursement pathways
- Reduces clinic buying friction
- Supports faster adoption
BrainsWay’s evidence-led promotion drives physician trust and repeat adoption
BrainsWay Ltd. leans on clinical proof, specialist education, and key opinion leaders to sell Deep TMS, because physicians want clear evidence before adopting a device. In 2025, that evidence-led message stayed tied to cleared indications and reimbursement support, which lowered buying friction for clinics. With 1,300+ installed systems worldwide, promotion also helps turn awareness into repeat use.
| Promotion lever | 2025 data | Why it matters |
|---|---|---|
| Clinical evidence | Peer-reviewed results | Builds physician trust |
| Installed base | 1,300+ systems | Supports repeat adoption |
| Reimbursement focus | Coverage support | Lowers clinic risk |
Price
Negotiated B2B pricing
BrainsWay’s pricing is typically negotiated B2B pricing, not a posted consumer list price. Its buyers are hospitals and clinics, so deals are usually set by contract, customer size, and region, often bundled with service and training. This fits a capital equipment market where one contract can cover multiple systems and recurring support.
Capital equipment sale
BrainsWay’s price is a capital equipment sale, so the customer pays for the Deep TMS system upfront rather than for a low-cost, one-time consumer item. This makes the core price tied to the system sale and service mix, with revenue recognized at delivery and installation, not at a small ticket level. In 2025, that means a higher-value, longer-sales-cycle purchase that can run into six figures per system.
Recurring service economics
BrainsWay’s pricing is not just a one-time system sale; medical devices often carry ongoing service, training, and support, which can extend revenue after installation. In 2024, BrainsWay reported about $37 million in revenue and had more than 1,000 systems installed worldwide, so each placement can support follow-on cash flow. That makes the model more recurring and helps deepen customer ties over time.
Reimbursement dependent value
BrainsWay Ltd.’s pricing has to fit reimbursement, not just the device sticker price. Clinics buy when payer coverage and patient access make each reimbursable treatment economically viable, so value depends on the clinical bill code and the payer mix. In TMS, access has expanded, but out-of-pocket costs still rise fast when coverage is weak.
- Coverage drives clinic demand.
- Reimbursement sets true affordability.
- Patient access shapes utilization.
Leasing and financing potential
BrainsWay Ltd.'s leasing and financing option can cut a provider's upfront cash need, which matters for specialty devices that often require six-figure capital budgets. That structure can speed adoption in smaller practices, where preserving liquidity is often the main hurdle to buying new treatment tech.
- Lower upfront cost
- Helps small practices adopt
- Supports faster purchase decisions
BrainsWay Pricing Depends on Contracts, Reimbursement, and Clinic Demand
BrainsWay Ltd. uses negotiated B2B pricing, not a posted list price, so the final deal depends on contract size, region, service, and training. The Deep TMS system is a high-ticket capital sale, often financed or leased, and clinic demand still hinges on payer reimbursement and patient affordability. With 1,000+ systems installed worldwide, pricing also supports recurring support revenue.
| Price driver | Impact |
|---|---|
| Negotiated contract | Custom deal pricing |
| Reimbursement | Drives clinic adoption |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.